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ABSTRACT 
In nanomedicines, currently a wide array of reported nanoparticle systems is being explored by targeting schemes which suggests great 
potential of targeted delivery to revolutionize cancer therapeutics. This review  gives insight into recent  challenges in modification of 
nanoparticle systems for enhanced cancer therapy  acknowledged by researchers to date and also outlines different major targeting strategies of 
nanoparticle systems that have been utilized for the delivery of therapeutics or imaging agents, targeting ligand and cross-linking agent to cancer  
which was divided into three sections: 1) Angiogenesis associated targeting, 2) Uncontrolled cell proliferation targeting and 3) Tumor cell 
targeting. 
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1. INTRODUCTION 
Focusing on cancer, applied nanotechnology has been 
revolutionized in the field of cancer therapeutics with 
immense potential owing to recent advancements in 
nanoparticles (NPs) based drug delivery systems. The main 
goal of most nanoparticle (NP) system is to prevent the 
degradation of active therapeutic agents to achieve enhanced 
bioavailability and to regulate their pharmacokinetic profile. 
However, most drugs are associated with some limitations 
such as poor water solubility, improper size and surface 
area, biodistribution and targeting challenges, and low 
therapeutic index 1.  
To overcome these shortcomings, scientists are always in 
search for the improved, structurally stable therapeutic NPs 
that offer several advantages over the free drug which can 
improve the efficacy of treatment and decreases the 
possibility of the serious side effects2. 
In general, due to their distinctive characteristics like 
enormous surface area, high drug loading capacity, long 
circulation time in blood, controlled drug-release capacity, 
minimal toxicity, biocompatibility, storage stability, and 
flexibility in the route of administration, NPs have become 
prominent candidates for optimized cancer therapy through 
site specificity, avoidance of multi drug resistance and the 
systematic delivery of an therapeutic agent.  
1.1.  Recent Nanoparticle systems for cancer therapy: 
Recently there are several types of NPs are available for 
cancer treatment. Observing the development in the NPs in 
cancer disease treatments motivates the researchers to 
investigate its use in a various application such as protein 
NPs, liposomes, micelles, metallic NPs, carbon nanotubes, 
dendrimers, Protein- and peptide-drug conjugates, etc. 3, 4, 5, 
6.  The formulation development of the NP systems in 
functional moieties based on its physical characteristics, 
therefore, the site targeting of the drug can be possible to 
enhance the stealth properties of the NPs such as calculating 
time enhancement and positively enhanced endocytosis the 
hydrophilic surfaces would be used 7, 8.Table 1 showing the 
Liposomes, Natural Polymers, Synthetic Polymers, Micelles, 
Dendrimers, Iron-Oxide NPs, Gold NPs which have been used 
for clinical trial. 
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Table 1: The NPs with its physical properties explored for the clinical development. 
Commonly used NPs Size of NP Physical characteristics of NPs 
Quantum Dots  (Qds) 9 2-10 nm 
 
high fluorescence quantum yield broad absorption spectra and, 
high photostability 
Gold NPs 10 1-100 nm 
 
 They are high photo-thermal conversion rate, Gold Nanorods 
Intense light absorption. Different shapes and size are available. 
Good colloidal stability, biocompatibility and simple ligand 
conjugation chemistry. 
Silica 11 50-1000 nm 
 
Porous Silica NPs (Psi NPs) 
They have a large surface area with pore volume, have good 
thermal and chemical stability. They offers simple surface 
functionalization 
Iron-Oxide NPs 12 10-100 nm 
 
Super paramagnetic Iron-Oxide NPs (Spions) magnetic 
resonance imaging contrast agents use as clinical development, 
biodegradable, diverse formulations allow and Biocompatible 
Micelles13 10-100 nm 
 
Hydrophobic core acts as natural carrier environment, 
structural modifications, Unique core-shell architecture. 
Synthetic Polymers 
(PLGA)14 
50-300 nm 
 
This drug easily incorporated in a matrix and synthetic material  
is FDA approved 
 
 
Dendrimers15 5 – 20 nm 
 
Polyvalent, non-toxic, chemically stable, soluble and 
conjugation of the therapeutic agent. 
Albumin  as Natural 
Polymers16 
50-300nm 
 
non-toxic, biodegradable and Biocompatible, chemically modify,  
 
 
Carbon Nanotubes17 1-10nm 
 
high propensity, easily chemically modified, High carrying 
capacity 
 
Liposomes18 20 – 1000 nm 
 
lipophilic drugs, stability in-vivo, protect drugs from 
breakdown, low uptake by macrophages 
. 
 
1.1.1 Advantages of therapeutic Nanoparticles: 
The key part of the NPs is to revert the bioactive molecules 
physicochemical characteristics to required bio 
pharmacologic profiles, control release of bioactive agents, 
enhanced the therapeutic drug delivery and efficiency also 
NPs perform theranostic functions. 
Despite; the advantages offered by NPs, the challenges 
associated with it should be considered before formulating 
any therapeutic NPs; some of the challenges are as follows13 
(i) Non-targeted NPs could easily be recognized by 
mononuclear phagocyte system (MPS) present in blood, 
liver, spleen, lung, and bone marrow. 
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(ii) Surface hydrophobicity of NPs is a key factor for 
enhanced blood components adsorption onto the NP 
surface.  
(iii) Prolonged circulation time of NPs is a pre-requisite for 
in vivo administration until they reach the target site. 
(iv) Localization of NPs to the tumor following enhanced 
permeability and retention (EPR) effect could be 
hindered by abnormal tumor structure leading to 
ineffective drug uptake.  
1.1.2 These challenges can be overcome as follows: 
Surface modification of the NPs with appropriate targeting 
moieties could overcome these challenges to some degree 
since targeting agents would competently carry the active 
molecule to its specific site of action rather than undesired 
localization 15. This concept triggered the development of 
several approaches for structural modification of NPs. 
Although structural alterations of these NPs may control the 
reticulo endothelial system (RES) recognition via stealth 
mechanism, the efficacy of targeted NPs with definite 
progression has not been standardized yet. This review 
presents an overview of different NP targeting strategies 
with their advantages and limitations and recent challenges 
acknowledged by the researchers to date. 
This review will particularly focus on different targets being 
targeted by NPs, the possible techniques performed to 
conjugate NPs with targeting agents, and their biological 
responses in both in vitro and in vivo studies19. 
 
 
Table 2 Clinical development of nanomedicines for tumor targeting 
Bioactive 
compound 
NP Formulation Targeted ligand Name of 
the drugs 
Indication Status 
Doxorubicin PEGylated liposomes F(ab')2fragmentofhuman 
Ab GAH 
MCC-465 Metastatic stomach 
cancer 
 
 
 
 
 
 
 
 
Phase I 
 
Doxorubicin PeGylated liposomes Antigen-binding fragments 
(Fab) of cetuximab 
C225-ILS-
DOX 
Advanced solid tumors 
siRNA20 Cyclodextrin-
based(21) NP 
containing anti-
RRM2 
Transferrin CALAA-01 Various solid tumors 
siRNA22 Liposomes Protein kinase N3 Atu027 Solid tumors 
p53 gene Liposomes Anti-transferrin receptor 
single-chain Ab 
fragment(TfRscFv) 
SGT53 Solid tumors 
BikDD plasmid 
DNA 
Liposomes Proapoptotic gene C-vISA-
BikDD 
Pancreatic cancer 
Docetaxel PeGylated PL(G)A Small molecule BIND-014 
(Accurins™) 
Solid tumors  
Phase II 
Oxaliplatin Liposomes Transferrin MBP-426 Gastroesophageal 
Adenocarcinoma 
 
1.2.  NP Targeting Strategies  
Conventional therapies are rapidly eliminated from the body 
and suffer from widespread distribution into nontargeted 
organs and tissues 12, whereas targeted therapeutic NPs have 
gained promising attention through offering a “therapeutic 
strategy” to tackle the requirements for frequent drug 
administration, higher dose, and unwanted toxicities related 
to the conventional therapies 11. Therefore, an improvised 
treatment regimen with more patient convenience has 
become a necessity. Ideally, targeting refers to the specific 
localization of NPs to the desired site rather than 
indiscriminate distribution throughout the body. Before 
being accumulated to the diseased site, these targeted NPs 
are required to overcome external barriers, en route 
barriers, and cellular barriers 10. Effective design of an ideal 
delivery system is the key foundation to overcome these 
barriers. There are two major tumor targeting strategies, 
passive and active targeting, that have been widely studied 
17. These two strategies are correlated and work to efficiently 
deliver the drug particles to the target site. Passive targeting 
takes advantage of the pathophysiological feature of the 
diseased tissue, commonly tumor, while active targeting of 
drug carrier initially utilizes the benefits of passive targeting 
to accumulate into the tumor region and subsequently bind 
to the target cells using targeting ligand that leads to 
receptor-mediated internalization of NPs into the cells9. 
1.2.1. Passive Targeting: Advantages and Challenges.  
Passive targeting depends on tumor microenvironment, 
enhanced permeability and retention (EPR) effect, and 
tumor pH to deliver therapeutic agents from the 
nanocarriers. Passive drug targeting is widely exploited in 
cancer therapy because NPs circulating in the bloodstream 
can be localized to cancerous tissues through the well-
known EPR  effect and helps drugs to expose directly at the 
tumor tissue bypassing systemic metabolism 23, 24 
Anatomically, inherent leaky tumor microvasculature is 
present in cancerous tissues which are characterized by 
abnormal branching and enlarged inter-endothelial gaps 
which results in breakdown of tight junctions between 
endothelial cells and a disrupted basement membrane24. 
This leaky and defective vascular architecture created due to 
the rapid vascularization and large gaps between endothelial 
cells which is a vital component to augment the neoplastic 
environment which is coupled with poor lymphatic drainage 
allows the famous EPR effect 25, 26. Thus, EPR effect has 
become a guiding principle for the development of cancer 
targeting drug design.  
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But, EPR effect is involved with few challenges since 
macromolecules or NPs can invade into the tumor tissue 
only if they can avoid the RES and renal clearance. A drug 
should remain at least 6 hours in the circulation to get 
accumulated into the neoplastic tissues via EPR effect 27. EPR 
effect was reported unsuccessful to maintain stable 
circulation of NPs in the bloodstream due to size restrictions 
of the tumor fenestrations.  
The development of therapeutic nanocarriers with enhanced 
retention time is still under practical challenge, particularly 
in clinical tumors, where the blood vessel morphology is 
very different than that of mice model used in preclinical 
studies. This could limit the intra tumoral distribution of NPs 
28. In addition, the blunt localization and accessibility of drug 
carriers into the tumor might not be feasible in case of 
certain tumors (lung cancer). The high interstitial pressure 
of solid tumors does not allow homogenous distribution of 
drugs in the tumor 
Recently, scientists are developing NPs that can adapt the 
tumor microenvironment to selectively target cancer cells. 
There are several NP formulations in preclinical and clinical 
trials that are able to tackle the microenvironment through 
inhibiting angiogenesis, suppressing tumor growth factors, 
and enhancing several immune cells (T cell, NK cells, and 
dendritic cells) 29. Despite the challenges, realistic clinical 
settings are necessary to obtain the benefit of the applied NP 
treatment. 
To date, there are several FDA approved NPs such as Doxil 
(1995), Feridex (1996), Mylotarg (2000), Zevalin (2002), 
Abraxane(2005,2013), Oncospar(2006), and Ontac (2008) 
that utilize enhanced permeability and retention (EPR) effect 
to accumulate in solid tumors 30 
1.2.2. Active Targeting: Advantages and Challenges.  
The term “active targeting” defines a cell-specific targeting 
ligand-receptor interaction by coupling with drug or 
nanocarrier with or without using cross-linking agents at the 
target site after reaching via blood circulation and 
extravasation. These targeting moieties have specific affinity 
for the cell surface antigens (e.g. receptors)and they can 
differentiate between normal and tumor cells based on the 
receptor or antigen expression levels(29). For example, 
using Herceptin targeted NPs helped to differentiate human 
epidermal growth factor receptor 2 (EGFR), human 
epidermal receptor-2 (HER2) positive and (HER2) negative 
breast cancer cells. Clearly, the active targeting of HER2 
receptors on the over-expressed cells with NPs was 
confirmed30.  
However, active targeting drug delivery system has many 
limitations such as very difficult to predict the effectiveness 
of the active targeted drug, very poor penetration in tumor 
site, to manage NPs complexity and very poor familiarity 
regarding the physiologic and biological structure of the 
tumor. Although, this treatment has main advantages to use 
vascular targeted NPs which can be used to cure or protect 
the problems in the target drug delivery system31.  
1.2.3 Active targeting strategy for development site-
directed NPs  
As discussed in the above sections the passive targeting has 
many limitations to accumulated the drug at the site 
locations, therefore, the research and development is further 
going on the active targeting to reach the maximum 
effectiveness in the targeting drug delivery system 32, 33. To 
improve accumulation of the drug into the tumor site the 
polymeric NPs are the versatile solution because it has 
multifunctional structures which can be modified 34, 35. The 
modification of the ligand surface and little changes in the 
polymeric composition leads the targeting effectiveness in 
concerned biological systems. The various types of affinity 
ligands were used in active targeting which can help into the 
NPs binding, can be used as antigens and they act differently 
in diseased tissue and plasma membrane36. In addition to 
this such drug delivery system can be used as intracellular or 
extracellular compartment controlled released drug. 
Therefore, the primary function of the targeting ligand is to 
cell internalization by active targeting NPs, enhanced the NPs 
uptake into the targeted cell and enhanced the therapeutic 
efficacy. The biodistribution is majorly related to NPs 
colloidal properties, therefore, the enhancement of cell 
uptake at target sites and cell recognition would be possible 
through the targeting ligands. The clinical trials are currently 
in the progress for the widely accepted active targeting drug 
delivery systems 37, 38.  
2. TARGETING RECEPTORS FOR CANCER THERAPY: 
2.1 Angiogenesis-associated targeting receptors 
Angiogenesis is the physiologic process by which new blood 
vessels are formed from pre-existing vessels which involves 
tight regulation of several signaling pathways. It occurs 
primarily during human development and enhanced 
permeability and retention (EPR) production; though, 
abnormal regulation of angiogenesis process was also found 
in various pathologic conditions, including cancer.  
Targeting receptors coupled with angiogenesis in malignancies 
mainly involves integrins and vascular endothelial growth 
factor (VEGF) molecule and its associated VEGF receptors39. 
Among Vascular Endothelial Growth Factor Receptors 
(VEGFR), VEGFR-2 plays a significant role in angiogenesis 
and highly expressed frequently in human cancers. Integrins 
(αvβ3and others) belongs to a vast family of hetero dimeric 
transmembrane cell-adhesion receptors which have been a 
NP preferentially expressed on the angiogenic endothelium 
in malignant tissues. 
The angiogenesis targeting has become a wider area of 
interest for cancer therapeutics as it is known to cause the 
invasion, migration, and proliferation of smooth muscle and 
endothelial cells, which results in degradation of the 
basement membrane and formation of a new lumen 
structure. Thus, angiogenesis appears to be one of the most 
critical steps in tumor transformation to the metastatic form, 
having the ability to spread to other parts of the body40. 
The main angiogenic targets investigated for NP systems for 
therapeutic beneﬁt includes various receptors involved in 
malignancies are the VEGFRs, αvβ3 integrins, Matrix Metallo-
Proteinase Receptors (MMPs), and Vascular Cell Adhesion 
Molecule-1 (VCAM-1). 
2.2 Vascular endothelial growth factor receptor (VEGFR) 
VEGFR induces the tumor angiogenesis significantly, 
therefore, the development of the antibodies, peptide and 
any methods for targeting to the VEGFR. It has also the 
potential to function as a targeting receptor in prostate and 
breast cancer.  In neoplastic cells, the oncogenes and Tumor 
hypoxia regulate VEGF, therefore, VEGFR-1 and VEGFR-2 
upregulated41.  
2.3 αvβ3 Integrin 
Hetero dimeric transmembrane endothelial cell-adhesion 
receptors include the αvβ3 integrin as one of the family 
members. The targeting strategy for the αvβ3 integrin has 
centered non-peptide mimetic. The ligand for the drug 
delivery induced by the non-peptide mimetic, non- 
peptidomimetics coupled to a NP for anti-angiogenesis 
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therapies42. Generally, endothelial cells producing in 
neovascular endothelial which is producing the angiogenesis 
and increase the endothelial cell interaction and locomotion 
43. The αvβ3 integrin intrinsically associated with calcium-
dependent signaling and VEGFR-2 signaling would be 
helpful in the endothelial cell migration.  The important 
outcome of the research is that integration of the αvβ3 
integrin with the active targeting leads the treatment 
efficiency and enhanced the anti-angiogenic treatments44.   
2.4 Vascular cell adhesion molecule (VCAM) 
VCAM-1 binds integrins to extracellular matrix proteins 
during the angiogenesis and relocation of the tumor.  The 
VCAM-1 expressed on the endothelial cells surface and it was 
closely appears to various cancer cell metastasis and helps in 
the cell to cell adhesion. VCAM-1 expression increased in 
cancer which is linked to leukemias and lymphomas. This 
includes the lung, renal cell carcinoma, Hodgkin's disease, 
nephroblastoma, B-cell lymphocytic leukemia and breast 
cancer45. First time targeted in vivo study of VCAM-1 based 
on immuno-liposomes46 and its results state that the 
accumulation is extensive in the endothelial cells in mice 
tumor47.  
In addition to this VCAM-1 targeting has localized liposomes 
tumor vasculature. The lower degree of the localization was 
found in VCAM-1 targeting in localize liposomes in tumor 
vasculature in comparison to non-specific liposomes. 
Fluorescence microscopy could find the tumor sections 
where immuno-liposomes were found. Non-targeted 
liposomes lower fluorescence intensity because of the 
dilution of liposomes throughout the tumor and high degree 
of extravasations 48. 
2.5 Matrix metalloproteinase 
Structurally related zinc-dependent endopeptidases include 
the matrix metalloproteinase (MMPs). In this degradation of 
an extracellular matrix similar to vascular cell adhesion 
molecule-1 and αvβ3 integrin. The fundamental 
physiological MMPs component used for repairs the tissue, 
angiogenesis, and morphogenesis49. In addition to this, it also 
plays a key role in pathological conditions of tumor 
metastasis. The MMPs major function in NP system is 
activated to MMP-2 by membrane type-1 MMP 50. Membrane 
type-1 MMP plays a significant role in migration, degradation 
of extracellular matrix, capillary tubes formation, 
recruitment of accessory cells and endothelial cell invasion. 
They are attached with the angiogenesis and metastasis, 
therefore, it was noticed that it is overexpressed in certain 
types of tumor cells, breast, lung, gliomas, and cervical 
carcinomas. Finally, membrane type-1 MMP enhanced the 
binding activities of the ligand by utilizing the αvβ3 
integrin51. 
3. UNCONTROLLED CELL PROLIFERATION 
TARGETING RECEPTORS 
In cancer, cell proliferation receptors play an important role 
to enhance the cancer tumor; therefore, these receptors are 
to be targeted in cancer therapeutics.  The active targeting is 
mostly used to target cell proliferation receptors52. Basically, 
there are four monoclonal antibodies targeting criteria such 
as an antigen is overexpressed by the cancer cell, antigen 
participates in the cancer disease, the stability of antigen is 
depending upon the tumor cell surface and antigen can be 
classified in a variety of tumor cell and expressed by a huge 
percentage53. There are several actively targeting NPs were 
used as folate receptors, transferrin receptors, human 
endothelial receptors. 
 
3.1 Human epidermal receptor (HER) 
The HER is basically tyrosine kinases group member. These 
receptors offer highly up-regulated targets to the tumor cell 
surface.  The HER -2 and epidermal growth factor receptor 
(EGFR) are investigated in the tyrosine kinases family 
receptors. These receptors have potential in the cancer 
therapy as binding the endogenous growth factor ligand and 
mediate a cell for its growth.  Amphiregulin, Epidermal 
Growth Factor, Epiregulin and Betacellulin are the 
endogenous EGFR ligand and they are used as targeting 
methods 54.   The high growth of the EGFR in the solid tumor 
indicates the advanced stage of the tumor and it is EPR effect 
presenting the metastatic capabilities in different cancer. In 
the various tumor such as in colorectal, breast, brain cancers 
and breast epidermal growth factor receptor is 
overexpressed in these tumors.  For the neck and head 
cancer the Cetuximab, a monoclonal antibody cancer 
treatment is recently used55 and its performance can be 
improving by combination with growth factor receptor 
therapy. Recently the HER-2 is widely used for mAb-based 
therapeutic strategies as attractive targeting56. Trastuzumab, 
a monoclonal antibody is designed and developed for 
antagonizing HER -2 function and approved the FDA. 
3.2 Transferrin receptors 
Transferrin receptors are nothing but the serum non-heme 
iron-binding glycoprotein and it is a very important type of 
receptor for cancer treatment because it can help to 
transport iron to proliferating cells57.  The direct interaction 
of the transferrin receptors to its ligand transferrin or 
monoclonal antibodies mAbs specific, placental tissue, 
rapidly proliferating cells, endothelial cells of the blood-
brain barrier58 are the important factor of this transferrin 
receptor. The transferrin receptors when binds upon the cell 
surface at that time transferrin is endocytosed into acidic 
compartments. The transferrin receptors are also available 
for the human clinical trials such as Diphtheria toxin, 
Cisplatin and Adriamycin59. 
3.3 Folate receptors 
The 38 kDa glycosyl-phosphatidylinositol-anchored 
glycoprotein is a folate receptor. This receptor is found 
highly in the research area for the treatment of cancer.  The 
density of the folate receptor increases when the advanced 
stage cancer is detected which can improve the targeting 
efficiency and restricts or reduces the cancer tumor 
disease60. Therefore, the polarized epithelial apical 
membrane binding with the folate receptor can help I the 
tumor targeting also can help to protect the healthy cells. In 
folate, the antibodies and folic acid are used as targeting 
ligand. These receptors are nontoxic, inexpensive, non-
immunogenic, stable in storage, easy to conjugate to carriers, 
retain high binding affinity. 
The folate receptors have potential in many types of cancer 
such as breast cancer, lung, head, neck, brain and renal cell.  
The doxorubicin and paclitaxel have folate receptor-targeted 
liposomes which can be used to avoid the multidrug folate 
receptor as a chemotherapeutic agent61.  
4. TUMOR CELL TARGETING RECEPTORS 
The research data of American Cancer Society cancer 
statistics state that the maximum death of human being by 
the various types of cancer in 2008. They have estimated 
that the 40,930,161840,49960 and 28660 death due to 
breast, lung, colorectal and prostate cancer respectively62.    
To cure cancer there are various methods described in the 
angiogenesis sections for tumor cell targeting and 
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uncontrolled cell proliferation. However, there are many 
other targeting methods for the particular cancer treatment 
such as the NPs systems are specifically coupled with 
particular cancer rather than universal cancer. 
4.1 Targeting to breast cancer 
The human epidermal receptor-2 used as targeting to the 
breast cancer is one of the oldest technologies as drug 
delivery. The Trastuzumab is a monoclonal antibody is 
approved by the FDA in 1998 to act against HER-2. The HER-
2 positive tumor can be cured by the Targeted poly NPs 
with the model toxin63. In breast cancer, quantum-dot 
loaded chitosan NPs and cross-linked human serum 
albumin NPs are provide effective treatment with HER -2 
targeting. 
The folate receptors are also used as cancer treatment and it 
can improve the effect on tumor site.  In breast cancer cell 
the targeted folic acid-conjugated PEGylated magnetite NPs 
entered easily in comparison to the surface of non-PEGylated 
NPs. The paclitaxel-loaded NPs with lactic acid and ethylene 
glycol gave an improvement in anticancer activity and cell 
internalization. Luteinizing hormone-releasing hormone 
receptor can be used to detect the metastasized and localized 
breast cancer and widely used as an anticancer agent and 
targeted delivery. The luteinizing hormone-releasing 
hormone conjugated super-paramagnetic iron oxide with 
luteinizing hormone-releasing hormone positive cell help in 
separation of the NPs which is segregated in the liver64.  
4.2 Targeting colorectal cancer 
The development of many antibodies for the treatment of 
colorectal cancer is available. Panitumumab, Cetuximab and 
Avastin antibodies approved by FDA in the year of 2004 to 
2006. Avastin, Panitumumab and Cetuximab antibodies are 
humanized monoclonal which act against the HER-1, EGFR 
and VEGF and used for the advanced colorectal cancer.  
These approved antibodies have potential as targeting drug 
delivery system and give advancement in the nanocarriers. 
During the delivery of payloads, it produces the synergetic 
effects and inhibiting cancer pathways. 
Targeting moieties interact with cancer cell in colorectal 
cancer, therefore, this development is most viable and 
considered as novel development for colorectal cancer. 
Guanylyl cyclase C receptors are used for the metastatic and 
localized colorectal cancer which considered the novel 
targeting approach because it interacts and overexpressed 
with the bacterial enterotoxins of colorectal cancer cells.  
Moreover, for the batter treatment in colorectal cancer 
the polymeric conjugates have been used.  
4.3 Targeting to prostate cancer 
In the prostate cancer, the prostate-specific membrane 
antigens are the main targeted antigen in the prostate cancer 
treatment which is also known as overexpressed cancerous 
tissue. The prostate speciﬁc membrane antigen efficiently 
working in the LNCaP prostate cancer cell line and it is class 
II transmembrane glycoprotein.  The aptamers speciﬁc to 
prostate speciﬁc membrane antigen used as the targeting and 
found anticancer agent in the prostate cancer as per the 
research data available from the MIT and Harvard. 
The current development in the surface modification of the 
NPs enhances the targeting efficiency. Aptamers surface 
density range is well defined therefore it enhance tumor 
targeting but it was observed that its effects to protective 
PEG shells. Also, it can be rapid to isolate the NP in the 
spleen and liver. Prostate speciﬁc membrane antigen is also 
well known as bind folate ligands prostate cancer targeting. 
to target the prostate cancer Folate-conjugated lipid NPs 
have been used. Other receptors such as Sigma receptors 
would be used as targeting receptor in prostate cancer 
and finally enhanced the therapeutic efficiency65. 
5. CONCLUSION 
Application of various targeted NP system promises for 
more effective delivery to the region of interest which has 
resulted in the development of novel multifunctional 
delivery methods to treat cancer. NP systems have the 
ability to target various portions of the tumor utilizing 
specific targeting moieties, optimize the loading and 
optimally improve the release of nanocarrier and thus EPR 
effect problems associated with multi-drug resistance. 
Moreover, most of the targeting moieties provide synergistic 
antitumor effects as there is a large overlying in the types of 
targets. The research for more molecular targets needs to be 
undertaken to advance the ability of targeted nanocarrier 
which could alter biodistribution by enhancing overall 
efficacy and specificity of nanocarrier at the tumor site and 
decreases toxicity to normal tissue.  
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